Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,516 total articles

Stifel Lowers Figma Price Target, Citing AI-Driven Margin Uncertainty

Stifel Lowers Figma Price Target, Citing AI-Driven Margin Uncertainty

Stifel reduced its price target on Figma Inc. (NYSE: FIG) from $40 to $30 while retaining a Hold rating. The new target implies roughly 20% upside from the stock's recent price of $24.89. The move follows Figma's better-than-expected fourth-quarter results and upbeat 2026 revenue guidance, but Stifel flagged uncertainty about how increased AI inves…

HSBC Starts Coverage on PicPay with Buy Rating, $21 Target

HSBC Starts Coverage on PicPay with Buy Rating, $21 Target

HSBC launched coverage of PicPay (PICS) with a Buy recommendation and a $21 price objective, implying roughly 59% potential upside from the current market price of $15.48. The bank based its valuation on a dividend discount model using a 15% cost of equity and 8.0% growth rate. HSBC highlights PicPay's rapid revenue expansion and robust liquidity, …

Cantor Fitzgerald Sticks With Overweight on Analog Devices, Cites Cyclical Momentum and Company-Specific Strengths

Cantor Fitzgerald Sticks With Overweight on Analog Devices, Cites Cyclical Momentum and Company-Specific Strengths

Cantor Fitzgerald kept an Overweight rating and a $400 price target on Analog Devices (NASDAQ: ADI), highlighting modest quarterly outperformance, a strong raise, and sector- and company-specific drivers including automated test equipment, automotive dealer electronic fulfillment, and data center power and optical applications. The firm attributes …

Cantor Fitzgerald Reaffirms Overweight on NewAmsterdam Pharma, Keeps $49 Target Ahead of Key 2026 Catalysts

Cantor Fitzgerald Reaffirms Overweight on NewAmsterdam Pharma, Keeps $49 Target Ahead of Key 2026 Catalysts

Cantor Fitzgerald maintained an Overweight rating and a $49.00 price target on NewAmsterdam Pharma Co NV (NASDAQ:NAMS) after the company released fourth-quarter results. The target implies roughly 42% upside from the stock's current $34.56 level, though InvestingPro data indicates the share price may exceed its Fair Value. Multiple near- and mid-te…

Cantor Keeps eBay at Neutral, $90 Target After Strong Q4; Depop Deal and Buyback Pace Highlight Capital Plan

Cantor Keeps eBay at Neutral, $90 Target After Strong Q4; Depop Deal and Buyback Pace Highlight Capital Plan

Cantor Fitzgerald left its Neutral rating and $90 price target on eBay Inc. after the company reported fourth-quarter results that modestly exceeded expectations. Management outlined fiscal 2026 guidance roughly in line with fiscal 2025 for gross merchandise volume (GMV) and non-GAAP operating income, confirmed a $1.2 billion agreement to acquire D…